Press release
Insightful Analysis of the Nonalcoholic Steatohepatitis Therapeutics Market: Trends and Growth Forecast -2031
Nonalcoholic Steatohepatitis Therapeutics
In 2021, the global nonalcoholic steatohepatitis therapeutics market reached a valuation of US$ 10.1 billion and is poised to grow at a robust CAGR of 13.6% from 2022 to 2031, surpassing a forecasted value of US$ 20.2 billion by 2031. This section provides an overview of market size, growth rate, and historical data analysis, laying the foundation for a detailed exploration.
Request Brochure of Nonalcoholic Steatohepatitis Therapeutics Market Research Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691
Analysts' Viewpoint on Global Nonalcoholic Steatohepatitis Therapeutics Market Scenario
With no FDA-approved drug for NASH treatment, pharmaceutical companies are expected to introduce pipeline drugs to address this silent liver disease. The market is driven by the global rise in diabetes and obesity prevalence rates, coupled with increased awareness of available treatments. Manufacturers are engaging in clinical trials, particularly for Elafibranor, to enhance treatment efficacy and credibility. Strategic mergers, acquisitions, and research collaborations are recommended to launch innovative products for NASH treatment.
Overview of Global Nonalcoholic Steatohepatitis Therapeutics Market
NAFLD and its advanced form, NASH, pose significant health challenges globally. With obesity and insulin resistance as major contributing factors, the demand for effective treatments is escalating. NASH progression to liver cirrhosis underscores the urgent need for therapeutic interventions, driving market growth.
Surge in Prevalence of Nonalcoholic Steatohepatitis Disease Globally
NASH, a type of liver disease prevalent among non-alcoholic individuals, is characterized by liver fat deposition and inflammation. The increasing incidence of NASH is driving demand for therapeutics, with multiple drugs being launched to alleviate the disease burden. However, poor diagnostics and lack of proper diagnostic techniques pose challenges to market growth.
Rise in Investments in Drug Research and Development to Drive Global Market
Pharmaceutical companies are intensifying research and development efforts to address the unmet need for NASH therapeutics. Outsourcing of drug development processes and increased investment in R&D are facilitating innovation and accelerating drug discovery timelines. Despite cost-cutting pressures, investments in drug research remain robust, driven by the growing burden of NASH globally.
Increase in Number of People with Diabetes and Obesity to Propel Global Market
The escalating prevalence of diabetes, obesity, and high cholesterol levels is contributing to the rise in NAFLD and NASH cases globally. Urgent treatment methods are required to manage these conditions effectively, driving demand for NASH therapeutics. Advancements in technology and ongoing research efforts aim to develop more effective treatment options to address the growing disease burden.
Request for Analysis of COVID-19 Impact on Nonalcoholic Steatohepatitis Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=7691
Impact of COVID-19 on Global Nonalcoholic Steatohepatitis Therapeutics Market
The COVID-19 pandemic has impacted healthcare services, leading to a decline in NASH therapy, detection, and follow-up. Disruptions in drug clinical trials have further compounded challenges in NASH management. However, the etiology of COVID-19 liver injury has underscored the importance of liver health, highlighting the need for continued research and innovation in NASH therapeutics.
Elafibranor Reduces Liver Fat, Gains Preference for Treatment of NASH
Elafibranor, among other potential phase III candidates, emerges as a key player in the NASH therapeutics market. Its ability to reduce liver fat and positive outcomes in phase 3 clinical trials position it as a promising treatment option. With no existing medicine for NASH, Elafibranor holds significant market potential, driving its preference among healthcare providers and patients.
Cost-cutting Pressure from Regulatory Bodies to Restrain Market Growth
Government initiatives aimed at cost-cutting, coupled with increasing pressure from insurers and payers, pose challenges to market growth. Pharmaceutical companies face pricing pressures and demand for cost-effective treatment options, particularly in developing countries. Addressing these concerns while ensuring continued innovation is crucial for sustained market growth.
Regional Outlook of Global Nonalcoholic Steatohepatitis Therapeutics Market
North America dominates the global NASH therapeutics market, driven by a high prevalence of diabetes, obesity, and lifestyle changes. Europe, particularly countries like Italy, Spain, Germany, the U.K., and France, also presents lucrative opportunities for NASH therapeutics due to rising disease prevalence. Strategic market expansion efforts are recommended to capitalize on regional growth prospects.
Analysis of Key Players in Global Nonalcoholic Steatohepatitis Therapeutics Market
The global NASH therapeutics market is characterized by a highly fragmented landscape, with key players focusing on product innovation and strategic collaborations. Profiles of leading companies such as Intercept Pharmaceuticals, GENFIT SA, and Gilead Sciences offer insights into their strategies and market positioning. The competitive landscape section provides a comprehensive overview of key players and their market share analysis.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Insightful Analysis of the Nonalcoholic Steatohepatitis Therapeutics Market: Trends and Growth Forecast -2031 here
News-ID: 3379868 • Views: …
More Releases from Transparency Market Research
Functional Coffee Market Expanding at 7.6% CAGR Through 2035 - By Product Type / …
The global functional coffee market was valued at US$ 21.5 Bn in 2024 and is projected to reach US$ 48.1 Bn by 2035, expanding at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2035. This steady growth trajectory reflects the strong convergence of coffee consumption habits with rising demand for functional and wellness-oriented beverages. Functional coffee has transitioned from a niche category to a mainstream product offering,…
Global Electric Face Cleanser Market Poised for Robust Growth, projected to Reac …
The global electric face cleanser market is witnessing a transformative growth phase as consumers increasingly integrate advanced skincare technologies into their daily routines. Valued at USD 9.8 billion in 2025, the market is projected to expand significantly and reach USD 23.6 billion by 2036, growing at a healthy compound annual growth rate (CAGR) of 8.6% from 2026 to 2036. This growth trajectory underscores the rising importance of personal care technology,…
Asthma and COPD Drugs Market to Reach US$ 82.2 Billion by 2036, Growing at 5.7% …
The global asthma and COPD drugs market demonstrated strong fundamentals in 2025, with a valuation of US$ 44.7 Bn, reflecting the essential and recurring nature of respiratory therapeutics. Supported by a growing patient base and continuous pharmaceutical innovation, the market is projected to reach US$ 82.2 Bn by 2036, expanding at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2036.
This growth trajectory highlights the increasing reliance on…
Low-Alcohol Beverages Market Outlook 2035: Global Industry Set to Expand from US …
The global low-alcohol beverages market is undergoing a structural transformation as consumers increasingly prioritize health, moderation, and mindful drinking without sacrificing taste or social experiences. Valued at US$ 2.1 billion in 2024, the market is projected to reach US$ 4.6 billion by 2035, expanding at a healthy CAGR of 7.5% from 2025 to 2035. This sustained growth reflects changing lifestyle preferences, generational shifts in alcohol consumption, and continuous innovation by…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
